ANL Stock Summary and Trading Ideas (Adlai Nortye Ltd. - American Depositary Shares | NASDAQ:ANL)

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Adlai Nortye Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ANL.

As of February 20, 2026, ANL stock price declined to $9.74 with 26,680 million shares trading.

ANL has a beta of 0.63, meaning it tends to be less sensitive to market movements. ANL has a correlation of 0.00 to the broad based SPY ETF.

ANL has a market cap of $359.41 million. This is considered a Small Cap stock.

ANL has outperformed the market in the last year with a return of +340.4%, while the SPY ETF gained +13.4%. In the last 3 month period, ANL beat the market returning +567.1%, while SPY returned +4.1%. However, in the most recent 2 weeks ANL has underperformed the stock market by returning -3.9%, while SPY returned +1.5%.

ANL support price is $8.64 and resistance is $11.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANL shares will trade within this expected range on the day.